Sweety Asija
Mumbai, MH, India
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Mass spectrometry-based proteomics in glioblastoma - current understanding and future impact.
Journal: Brain research
Published: May 27, 2025
Correction: Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study.
Journal: Blood cancer journal
Published: May 20, 2025
Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study.
Journal: Blood cancer journal
Published: December 17, 2024
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study.
Journal: The Lancet. Haematology
Published: October 23, 2024
CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?
Journal: European journal of haematology
Published: June 02, 2023
Oncolytic immunovirotherapy for high-grade gliomas: A novel and an evolving therapeutic option.
Journal: Frontiers in immunology
Published: December 07, 2022
Clinical utility of CAR T cell therapy in brain tumors: Lessons learned from the past, current evidence and the future stakes.
Journal: International reviews of immunology
Published: October 03, 2022
Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Journal: International reviews of immunology
Published: August 08, 2022
Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation.
Journal: Frontiers in immunology
Published: February 28, 2022
Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells.
Journal: Molecular cancer therapeutics
Published: June 10, 2020
Showing 1-10 of 10
Last Updated: 09/26/2026